148 related articles for article (PubMed ID: 37208840)
21. Clinical Significance of Multi-Cancer Genome Profiling: Data from a Single Hospital in Japan.
Aoyama R; Nishikubo H; Kawabata K; Kanei S; Yamamoto Y; Nishimura S; Yashiro M
Cancer Genomics Proteomics; 2024; 21(1):79-87. PubMed ID: 38151295
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
[TBL] [Abstract][Full Text] [Related]
23. Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy.
Yoshii Y; Okazaki S; Takeda M
Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440540
[TBL] [Abstract][Full Text] [Related]
24. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
25. Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan.
Yamaguchi T; Ikegami M; Aruga T; Kanemasa Y; Horiguchi SI; Kawai K; Takao M; Yamada T; Ishida H
Int J Clin Oncol; 2024 May; ():. PubMed ID: 38795236
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.
Nakamura Y; Yamashita R; Okamoto W; Komatsu Y; Yuki S; Ueno M; Kato K; Taniguchi H; Kagawa Y; Denda T; Hara H; Esaki T; Moriwaki T; Sunakawa Y; Oki E; Nagashima F; Nishina T; Satoh T; Kawakami H; Yamaguchi K; Ohtsubo K; Kato T; Horita Y; Tsuji A; Yasui H; Goto M; Hamamoto Y; Wakabayashi M; Ikeno T; Shitara K; Bando H; Tsuchihara K; Miki I; Ichiki H; Ohtsu A; Yoshino T
JCO Precis Oncol; 2023 Mar; 7():e2200653. PubMed ID: 36996376
[TBL] [Abstract][Full Text] [Related]
27. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
Shirota H; Komine K; Takahashi M; Takahashi S; Miyauchi E; Niizuma H; Tada H; Shimada M; Niihori T; Aoki Y; Sugiyama I; Kawamura M; Yasuda J; Suzuki S; Iwaya T; Saito M; Saito T; Shibata H; Furukawa T; Ishioka C
Cancer Med; 2023 Mar; 12(5):6170-6181. PubMed ID: 36251535
[TBL] [Abstract][Full Text] [Related]
28. The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan.
Sunami K; Naito Y; Aimono E; Amano T; Ennishi D; Kage H; Kanai M; Komine K; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Yoshino T
Int J Clin Oncol; 2021 Mar; 26(3):443-449. PubMed ID: 33385275
[TBL] [Abstract][Full Text] [Related]
29. Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: A prospective multicenter study.
Takada K; Kubo T; Kikuchi J; Yoshida M; Murota A; Arihara Y; Nakamura H; Nagashima H; Tanabe H; Sugita S; Tanaka Y; Miura A; Ohhara Y; Ishiguro A; Yokouchi H; Kawamoto Y; Mizukami Y; Ohnishi H; Kinoshita I; Sakurai A
Front Oncol; 2022; 12():988527. PubMed ID: 36119486
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
31. Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).
Leroy K; Audigier Valette C; Alexandre J; Boussemart L; Chiesa J; Deldycke C; Gomez-Rocca C; Hollebecque A; Lehmann-Che J; Lemoine A; Mansard S; Medioni J; Monnet I; Mourah S; Pierret T; Spaëth D; Civet A; Galoin S; Italiano A
PLoS One; 2023; 18(9):e0291495. PubMed ID: 37708140
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
33. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Tomlins SA; Hovelson DH; Suga JM; Anderson DM; Koh HA; Dees EC; McNulty B; Burkard ME; Guarino M; Khatri J; Safa MM; Matrana MR; Yang ES; Menter AR; Parsons BM; Slim JN; Thompson MA; Hwang L; Edenfield WJ; Nair S; Onitilo A; Siegel R; Miller A; Wassenaar T; Irvin WJ; Schulz W; Padmanabhan A; Harish V; Gonzalez A; Mansoor AH; Kellum A; Harms P; Drewery S; Falkner J; Fischer A; Hipp J; Kwiatkowski K; Lazo de la Vega L; Mitchell K; Reeder T; Siddiqui J; Vakil H; Johnson DB; Rhodes DR
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476329
[TBL] [Abstract][Full Text] [Related]
34. [Precision Medicine Provided by National Health Insurance].
Muto M; Kondo T; Matsubara J; Kanai M; Matsumoto S; Ashida K; Suga J; Mukai K
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1158-1163. PubMed ID: 32829347
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.
Fukada I; Mori S; Hayashi N; Hosonaga M; Xiaofei W; Yamazaki M; Ueki A; Kiyotani K; Tonooka A; Takeuchi K; Ueno T; Takahashi S
Cancer Sci; 2023 Dec; 114(12):4632-4642. PubMed ID: 37858313
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive genomic profiling: Does timing matter?
Thapa B; Ahmed G; Szabo A; Kamgar M; Kilari D; Mehdi M; Menon S; Daniel S; Thompson J; Thomas J; George B
Front Oncol; 2023; 13():1025367. PubMed ID: 36865796
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of Todai OncoPanel in the setting of approved comprehensive cancer genomic profiling tests in Japan.
Kage H; Shinozaki-Ushiku A; Ishigaki K; Sato Y; Tanabe M; Tanaka S; Tanikawa M; Watanabe K; Kato S; Akagi K; Uchino K; Mitani K; Takahashi S; Miura Y; Ikeda S; Kojima Y; Watanabe K; Mochizuki H; Yamaguchi H; Kawazoe Y; Kashiwabara K; Kohsaka S; Tatsuno K; Ushiku T; Ohe K; Yatomi Y; Seto Y; Aburatani H; Mano H; Miyagawa K; Oda K
Cancer Sci; 2023 Apr; 114(4):1710-1717. PubMed ID: 36601953
[TBL] [Abstract][Full Text] [Related]
39. [Current Status and Prospects of the Comprehensive Cancer Genome Profiling].
Imoto I; Fukue M; Takaiso N
Gan To Kagaku Ryoho; 2021 Jan; 48(1):7-11. PubMed ID: 33468714
[TBL] [Abstract][Full Text] [Related]
40. Clinical Benefit of Comprehensive Genomic Profiling for Advanced Cancers in India.
Mathew A; Joseph S; Boby J; Benny S; Veedu J; Rajappa S; Rohatgi N; Sirohi B; Jain R; Agarwala V; Shukla DK; Mehta A; Pramanik R; Talwar V; Maka V; Raut N
JCO Glob Oncol; 2022 Mar; 8():e2100421. PubMed ID: 35404667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
